Akero Therapeutics Inc (NASDAQ: AKRO) is 139.11% higher on its value in year-to-date trading and has touched a low of $21.02 and a high of $58.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKRO stock was last observed hovering at around $56.28 in the last trading session, with the day’s loss setting it -54.66%.
Currently trading at $1.62M, the stock is 4.03% and 19.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.83 million and changing 3827049% at the moment leaves the stock 46.77% off its SMA200. AKRO registered 101.98% gain for a year compared to 6-month gain of 98.06%. The firm has a 50-day simple moving average (SMA 50) of $47.0615 and a 200-day simple moving average (SMA200) of $38.284626.
The stock witnessed a 23.98% loss in the last 1 month and extending the period to 3 months gives it a 28.94%, and is 3.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.05% over the week and 4.89% over the month.
Akero Therapeutics Inc (AKRO) has around 63 employees, a market worth around $4.48B and $0.00M in sales. Distance from 52-week low is 167.32% and -3.78% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.21%).
The EPS is expected to shrink by -1.23% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Akero Therapeutics Inc (AKRO) Top Institutional Holders
331.0 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 110.83% of the company’s shares. The shares outstanding are 79.67M, and float is at 71.76M with Short Float at 10.80%. Institutions hold 109.29% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 6.88 million shares valued at $161.28 million. The investor’s holdings represent 9.9425% of the AKRO Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.59 million shares valued at $131.06 million to account for 8.0778 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.43 million shares representing 7.8542% and valued at over $127.43 million, while GENERAL ATLANTIC, L.P. holds 7.5679 of the shares totaling 5.23 million with a market value of $122.79 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Cheng Andrew, the company’s President and CEO. SEC filings show that Cheng Andrew sold 6,620 shares of the company’s common stock on Jun 18 ’25 at a price of $54.84 per share for a total of $0.36 million. Following the sale, the insider now owns 0.55 million shares.
Akero Therapeutics Inc disclosed in a document filed with the SEC on Jun 18 ’25 that Gangloff Scott A. (Chief Technology Officer) sold a total of 848 shares of the company’s common stock. The trade occurred on Jun 18 ’25 and was made at $54.84 per share for $46504.0. Following the transaction, the insider now directly holds 23452.0 shares of the AKRO stock.
Still, SEC filings show that on Jun 20 ’25, Lamy Patrick (Senior VP, Commercial Strategy) disposed off 875 shares at an average price of $54.59 for $47766.0. The insider now directly holds 31,698 shares of Akero Therapeutics Inc (AKRO).
